Piramal Plans Large-Scale Expansion of API Manufacturing Facilities

October 16, 2017
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management

Volume 12, Issue 11

Piramal is investing $55 million into the expansion of its API manufacturing capabilities and capacities across sites in North America and Asia.

Contract development and manufacturing organization (CDMO), Piramal Pharma Solutions, announced on Oct. 10, 2017 that it is investing $55 million into the expansion of its API manufacturing capabilities and capacities across sites in North America and Asia. Part of the investment will go into new state-of-the-art, multi-purpose plants with more than 270 kL of total capacity to support the current pipeline of approximately 80 late-stage programs that Piramal is currently assisting partners with.

The CDMO will also expand its potency footprint (new occupational exposure limit: ≥10 ng/m3) at its plant in Riverview, Michigan, while strengthening early development capabilities at its Ennore, India site through additions of GMP kilo labs and a pilot plant. To meet the needs of its European biotech customers, Piramal is adding early development capabilities in both drug substance and drug product to its Morpeth, United Kingdom facility. Support functions such as analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.

Piramal supports API development and manufacturing through an integrated model across its five sites in North America, Europe, and Asia. API development activities including route scouting and process development are conducted at facilities in Aurora (Canad), Ennore (India), and Riverview (US). These facilities are forward integrated with commercial API manufacturing units at Aurora (Canada), Ennore (India), Digwal (India), Morpeth (UK), and Riverview (US). 

Source: Piramal